SAN DIEGO, Aug. 13, 2026 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights and…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
